Key Highlights

  • Myriad Genetics (NASDAQ:MYGN) quoted USD 6.51, up 8.14%, in premarket trading on November 5, 2026, per the premarket quote, after results filed on November 4, 2026.
  • Third-quarter Revenue was USD 202.7 million, down 1% from USD 205.7 million, while the GAAP net loss widened to USD 43.9 million, or USD 0.46 per share.
  • On October 19, 2026 Myriad agreed to sell its Prenatal Health Business to Labcorp for USD 210 million in cash, plus inventory value at closing, with completion expected by early 2027.
  • Full-year 2026 revenue guidance is USD 780 million to USD 790 million with a higher midpoint, and cash and equivalents were USD 107.1 million on September 30, 2026.

Third-Quarter Results Land With a Deal Attached

Myriad Genetics (NASDAQ:MYGN) reported third-quarter 2026 results in an 8-K dated November 4, 2026. Revenue was USD 202.7 million, down 1% year over year from USD 205.7 million but up 6% from the prior quarter. Total test Volume was 377,000, down 2%. The GAAP net loss was USD 43.9 million, or USD 0.46 per share, against a loss of USD 27.4 million, or USD 0.29 per share, a year earlier. Adjusted net loss was USD 10.7 million. Adjusted EBITDA was a loss of USD 5.3 million versus a profit of USD 10.3 million. The company also detailed its October 19, 2026 agreement to sell Prenatal Health to Labcorp.

Segment Mix, Margins and the Cash Position

The segment detail explains why investors are focused on the divestiture. Cancer Care Continuum revenue was USD 123.9 million, up 1%, on 98,000 tests, up 4%. Mental Health, which includes GeneSight, delivered USD 39.5 million, up 2%, on 141,000 tests. Prenatal Health fell 12% to USD 39.3 million as volume dropped 11% to 138,000 tests. GAAP gross Margin was 67.9%, down 200 basis points, and adjusted gross margin was 68.2% against 70.1%. Cash and equivalents were USD 107.1 million against long-term Debt of USD 121.1 million. President and Chief Executive Officer Sam Raha said the company has made meaningful progress on its path to accelerate profitable growth.

Risks and What to Watch Next

The sale remains subject to customary conditions, including regulatory approvals, so completion by early 2027 is an expectation and not a certainty. Prenatal Health contributes roughly USD 160 million of the 2026 revenue outlook, which means the continuing business will be smaller once the transaction closes. Guidance for the 2026 adjusted gross margin is 66% to 67%, below the quarter's 68.2%. Premarket quotes also reflect thin early trading, so a move of 8.14% can narrow or reverse once regular volume arrives. Investors will watch the Labcorp closing timeline, the next quarterly update, and whether the Cancer Care Continuum unit keeps converting test volume growth into revenue growth.

Where Things Stand

The jump at Myriad Genetics (NASDAQ:MYGN) looks like a reaction to two pieces of news arriving together: a divestiture that converts a shrinking unit into USD 210 million of cash, and a raised revenue midpoint, rather than to a clean Earnings beat. Revenue slipped 1% and losses widened, so the quoted premarket gain of 8.14% rests on Balance Sheet repair and strategic focus. The sale price is large against the USD 107.1 million cash balance and the USD 121.1 million of long-term debt, but it is not yet closed. The next catalysts are regulatory progress on the Labcorp transaction and the following quarterly report.